Typical Clinical Trial Dosage Progression Gradual dose increases help the body adjust to the medication and may reduce gastrointestinal side effects
For Research Use Only Not intended to diagnose, treat, cure, or prevent any disease
Anti-inflammatory effects of GLP-1 medicines independent of weight loss Several GLP-1 medicines, including semaglutide, liraglutide, and exenatide, reduce plasma levels of C-reactive protein (CRP), a surrogate of systemic inflammation, in people with obesity or T2D
Sergey Terushkin, MD, FACS Bariatric Surgeon & Weight Loss Doctor in Hollywood, FL Looking for a trusted Weight Loss Doctor in Hollywood, FL
Comparative Incretin Research: Retatrutide has been studied in direct comparison with dual agonists like Tirzepatide and single agonists like Semaglutide in pre-clinical models, with research examining how the addition of GCGR agonism modifies metabolic outcomes providing direct pharmacological insight into the incremental value of each receptor target within the tri-agonist framework
The risk of hypoglycaemia is typically minor